- Home
- MAIA vs RFL Comparison
MAIA vs RFL Comparison
Compare MAIA & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- RFL
- Stock Information
- Founded
- MAIA 2018
- RFL 2017
- Country
- MAIA United States
- RFL United States
- Employees
- MAIA N/A
- RFL N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- RFL Real Estate
- Sector
- MAIA Health Care
- RFL Finance
- Exchange
- MAIA Nasdaq
- RFL Nasdaq
- Market Cap
- MAIA 56.3M
- RFL 61.4M
- IPO Year
- MAIA 2022
- RFL N/A
- Fundamental
- Price
- MAIA $1.58
- RFL $1.65
- Analyst Decision
- MAIA
- RFL
- Analyst Count
- MAIA 0
- RFL 0
- Target Price
- MAIA N/A
- RFL N/A
- AVG Volume (30 Days)
- MAIA 398.8K
- RFL 57.4K
- Earning Date
- MAIA 08-11-2025
- RFL 06-11-2025
- Dividend Yield
- MAIA N/A
- RFL N/A
- EPS Growth
- MAIA N/A
- RFL N/A
- EPS
- MAIA N/A
- RFL N/A
- Revenue
- MAIA N/A
- RFL $732,000.00
- Revenue This Year
- MAIA N/A
- RFL N/A
- Revenue Next Year
- MAIA N/A
- RFL N/A
- P/E Ratio
- MAIA N/A
- RFL N/A
- Revenue Growth
- MAIA N/A
- RFL 35.56
- 52 Week Low
- MAIA $1.40
- RFL $1.28
- 52 Week High
- MAIA $3.74
- RFL $3.19
- Technical
- Relative Strength Index (RSI)
- MAIA 45.57
- RFL 40.64
- Support Level
- MAIA $1.50
- RFL $1.66
- Resistance Level
- MAIA $1.73
- RFL $2.16
- Average True Range (ATR)
- MAIA 0.09
- RFL 0.11
- MACD
- MAIA 0.01
- RFL -0.02
- Stochastic Oscillator
- MAIA 42.86
- RFL 11.11
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.